Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis

被引:8
作者
Corma-Gomez, Anais [1 ]
Macias, Juan [1 ]
Ramon Lacalle-Remigio, Juan [2 ]
Tellez, Francisco [3 ]
Morano, Luis [4 ]
Rivero, Antonio [5 ]
Serrano, Miriam [6 ]
Jose Rios, Maria [7 ]
Jesus Vera-Mendez, Francisco [8 ]
Carlos Alados, Juan [9 ]
Miguel Real, Luis [10 ]
Palacios, Rosario [11 ]
De los Santos, Ignacio [12 ]
Imatz, Arkaitz [13 ]
Antonio Pineda, Juan [1 ]
机构
[1] Hosp Univ Valme, Unit Infect Dis & Microbiol, Seville, Spain
[2] Univ Seville, Fac Med, Div Prevent Med & Publ Hlth, Seville, Spain
[3] Hosp Univ Puerto Real, Fac Med, Unit Infect Dis, Cadiz, Spain
[4] Hosp Univ Alvaro Cunqueiro, Unit Infect Pathol, Vigo, Spain
[5] Hosp Univ Reina Sofia, Unit Infect Dis, Cordoba, Spain
[6] Hosp Univ Gran Canaria Dr Negrin, Unit Infect Dis, Las Palmas Gran Canaria, Spain
[7] Hosp Univ Virgen Macarena, Unit Infect Dis, Seville, Spain
[8] Hosp Gen Univ Santa Lucia, Sect Infect Med, Serv Internal Med, Cartagena, Spain
[9] Univ Hosp Jerez, Unit Clin Microbiol, Cadiz, Spain
[10] Univ Malaga, Fac Med, Unit Immunol Biochem Mol Biol & Surg, Malaga, Spain
[11] Hosp Virgen Victoria, Unit Infect Dis & Microbiol, Malaga, Spain
[12] Hosp La Princesa, Unit Internal Med & Infect Dis, Madrid, Spain
[13] Hosp Univ Bellvitge, Unit Infect Dis, Barcelona, Spain
关键词
HIV/HCV-coinfection; sustained virological response; direct-acting antivirals; hepatocellular carcinoma; liver decompensation; COINFECTED PATIENTS; LIVER-DISEASE; PROGRESSION; NUCLEOSIDE;
D O I
10.1093/cid/ciaa1111
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The aim of this study was to assess the impact of human immunodeficiency virus (HIV) infection on the risk of developing hepatocellular carcinoma (HCC) in patients infected with hepatitis C virus (HCV) who achieve sustained virological response (SVR) with direct-acting antiviral (DAA). Methods. Multisite prospective cohort study, where HCV-monoinfected patients and HIV/HCV-coinfected individuals were included if they met: (1) SVR with DAA-based combination; (2) liver stiffness (LS) >= 9.5 kPa previous to treatment; (3) LS measurement at the SVR time-point. The main endpoint was the occurrence of HCC. Propensity score (PS) was calculated to address potential confounders due to unbalanced distribution of baseline characteristics of HIV/HCV-coinfected and HCV-monoinfected patients. Results. In total, 1035 HCV-infected patients were included, 667 (64%) coinfected with HIV. After a median (Q1-Q3) follow-up time of 43 (31-49) months, 19 (1.8%) patients developed HCC (11 [3.0%]; HCV-monoinfected, 8[1.2%]; HIV/HCV-coinfected individuals; P = .013). In the multivariable analysis, HIV coinfection was associated with a lower adjusted risk of developing HCC (subhazard ratio [sHR] = 0.27, 95% confidence interval [CI]: .08-.90; P = .034). Predictors of HCC emergence were: HCV genotype 3 (sHR = 7.9, 95% CI: 2.5-24.9; P < .001), MELD score at SVR >10 (sHR = 1.37, 95% CI: 1.01-1.86; P = .043) and LS value at SVR (sHR = 1.03, 95% CI: 1.01-1.06, for 1 kPa increase; P = .011). Using inverse probability weighting method on the PS, HIV-infected patients had a lower risk of HCC (powered HR = 0.33, 95% CI: .11-.85). Conclusions. Among HCV-infected patients with advanced fibrosis, who achieve SVR with DAA, HIV coinfection seems to be associated with a lower risk of HCC occurrence. The underlying causes for this finding need to be investigated.
引用
收藏
页码:E2109 / E2116
页数:8
相关论文
共 34 条
  • [1] Antitumor activity of Type I and Type III interferons in BNL hepatoma model
    Abushahba, Walid
    Balan, Murugabaskar
    Castaneda, Ismael
    Yuan, Yao
    Reuhl, Kenneth
    Raveche, Elizabeth
    de la Torre, Andrew
    Lasfar, Ahmed
    Kotenko, Sergei V.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (07) : 1059 - 1071
  • [2] Human Immunodeficiency Virus Infection Does Not Worsen Prognosis of Liver Transplantation for Hepatocellular Carcinoma
    Aguero, Fernando
    Forner, Alejandro
    Manzardo, Christian
    Valdivieso, Andres
    Blanes, Marino
    Barcena, Rafael
    Rafecas, Antoni
    Castells, Lluis
    Abradelo, Manuel
    Torre-Cisneros, Julian
    Gonzalez-Dieguez, Luisa
    Salcedo, Magdalena
    Serrano, Trinidad
    Jimenez-Perez, Miguel
    Ignacio Herrero, Jose
    Gastaca, Mikel
    Aguilera, Victoria
    Fabregat, Juan
    del Campo, Santos
    Bilbao, Itxarone
    Jimenez Romero, Carlos
    Moreno, Asuncion
    Rimola, Antoni
    Miro, Jose M.
    [J]. HEPATOLOGY, 2016, 63 (02) : 488 - 498
  • [3] Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease
    Backus, Lisa I.
    Belperio, Pamela S.
    Shahoumian, Troy A.
    Mole, Larry A.
    [J]. HEPATOLOGY, 2019, 69 (02) : 487 - 497
  • [4] Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis
    Bang, Chang Seok
    Song, Il Han
    [J]. BMC GASTROENTEROLOGY, 2017, 17
  • [5] Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents
    Calvaruso, Vincenza
    Cabibbo, Giuseppe
    Cacciola, Irene
    Petta, Salvatore
    Madonia, Salvatore
    Bellia, Alessandro
    Tine, Fabio
    Distefano, Marco
    Licata, Anna
    Giannitrapani, Lydia
    Prestileo, Tullio
    Mazzola, Giovanni
    Di Rosolini, Maria Antonietta
    Larocca, Licia
    Bertino, Gaetano
    Digiacomo, Antonio
    Benanti, Francesco
    Guarneri, Luigi
    Averna, Alfonso
    Iacobello, Carmelo
    Magro, Antonio
    Scalisi, Ignazio
    Cartabellotta, Fabio
    Savalli, Francesca
    Barbara, Marco
    Davi, Antonio
    Russello, Maurizio
    Scifo, Gaetano
    Squadrito, Giovanni
    Camma, Calogero
    Raimondo, Giovanni
    Craxi, Antonio
    Di Marco, Vito
    [J]. GASTROENTEROLOGY, 2018, 155 (02) : 411 - +
  • [6] Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
    Carrat, Fabrice
    Fontaine, Helene
    Dorival, Celine
    Simony, Melanie
    Diallo, Alpha
    Hezode, Christophe
    De Ledinghen, Victor
    Larrey, Dominique
    Haour, Georges
    Bronowicki, Jean-Pierre
    Zoulim, Fabien
    Asselah, Tarik
    Marcellin, Patrick
    Thabut, Dominique
    Leroy, Vincent
    Tran, Albert
    Habersetzer, Francois
    Samuel, Didier
    Guyader, Dominique
    Chazouilleres, Olivier
    Mathurin, Philippe
    Metivier, Sophie
    Alric, Laurent
    Riachi, Ghassan
    Gournay, Jerome
    Abergel, Armand
    Cales, Paul
    Ganne, Nathalie
    Loustaud-Ratti, Veronique
    D'Alteroche, Louis
    Causse, Xavier
    Geist, Claire
    Minello, Anne
    Rosa, Isabelle
    Gelu-Simeon, Moana
    Portal, Isabelle
    Raffi, Francois
    Bourliere, Marc
    Pol, Stanislas
    Bonnet, Delphine
    Payssan-Sicart, Virginie
    Pomes, Chloe
    Bailly, Francois
    Beaudoin, Marjolaine
    Giboz, Dominique
    Hartig-Lavie, Kerstin
    Maynard, Marianne
    Billaud, Eric
    Boutoille, David
    Cavellec, Morane
    [J]. LANCET, 2019, 393 (10179) : 1453 - 1464
  • [7] RETRACTED: Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B A Korean Nationwide Cohort Study (Retracted Article)
    Choi, Jonggi
    Kim, Hyo Jeong
    Lee, Jayoun
    Cho, Songhee
    Ko, Min Jung
    Lim, Young-Suk
    [J]. JAMA ONCOLOGY, 2019, 5 (01) : 30 - 36
  • [8] Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals
    Corma-Gomez, A.
    Macias, J.
    Tellez, F.
    Freyre-Carrillo, C.
    Morano, L.
    Rivero-Juarez, A.
    Rios, M. J.
    Alados, J. C.
    Vera-Mendez, F. J.
    Merchante, N.
    Palacios, R.
    Granados, R.
    Merino, D.
    De Los Santos, I
    Pineda, J. A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 71 (09) : 2354 - 2362
  • [9] HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals
    Corma-Gomez, Anais
    Morano, Luis
    Tellez, Francisco
    Rivero-Juarez, Antonio
    Real, Luis M.
    Carlos Alados, Juan
    Jose Rios-Villegas, Maria
    Jesus Vera-Mendez, Francisco
    Palacios Munoz, Rosario
    Geijo, Paloma
    Macias, Juan
    Pineda, Juan A.
    [J]. AIDS, 2019, 33 (07) : 1167 - 1174
  • [10] HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response
    Hamdane, Nourdine
    Juhling, Frank
    Crouchet, Emilie
    El Saghire, Houssein
    Thumann, Christine
    Oudot, Marine A.
    Bandiera, Simonetta
    Saviano, Antonio
    Ponsolles, Clara
    Suarez, Armando Andres Roca
    Li, Shen
    Fujiwara, Naoto
    Ono, Atsushi
    Davidson, Irwin
    Bardeesy, Nabeel
    Schmidl, Christian
    Bock, Christoph
    Schuster, Catherine
    Lupberger, Joachim
    Habersetzer, Francois
    Doffoel, Michel
    Piardi, Tullio
    Sommacale, Daniele
    Imamura, Michio
    Uchida, Takuro
    Ohdan, Hideki
    Aikata, Hiroshi
    Chayama, Kazuaki
    Boldanova, Tujana
    Pessaux, Patrick
    Fuchs, Bryan C.
    Hoshida, Yujin
    Zeisel, Mirjam B.
    Duong, Francois H. T.
    Baumert, Thomas F.
    [J]. GASTROENTEROLOGY, 2019, 156 (08) : 2313 - +